
Jan 5 (Reuters) - Genelux Corp GNLX.O:
GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS
GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)
GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026